pharma · Fertility · INTI
Inhibitor Therapeutics
Inhibitor Therapeutics patent portfolio — 5 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Tampa, USA
- Founded
- 2013
- Employees
- 5
- Programs
- 2
- Drugs
- 2
- Patents
- 5
Inhibitor Therapeutics patents
5 pharmaceutical patents indexed for Inhibitor Therapeutics. 0 expire within 24 months.
Inhibitor Therapeutics has 5 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 11931402
Compositions for treating heart disease by inhibiting the action of mAKAP-β
granted -
US 11229679
Compositions for treating heart disease by inhibiting the action of mAKAPβ
granted -
US 10617737
Compositions for treating heart disease by inhibiting the action of mAKAP-β
granted -
US 9937228
Treatment of myocardial infarction by inhibiting the action of mAKAPβ
granted -
US 9132174
Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3)
granted
Frequently asked questions
How many patents does Inhibitor Therapeutics have?
5 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Inhibitor Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.